227 related articles for article (PubMed ID: 26476120)
1. Prostate Cancer in Elderly Men: Screening, Active Surveillance, and Definitive Therapy.
Roussel B; Ouellet GM; Mohile SG; Dale W
Clin Geriatr Med; 2015 Nov; 31(4):615-29. PubMed ID: 26476120
[TBL] [Abstract][Full Text] [Related]
2. Expert panel advocates surveillance for men with low-risk prostate cancer.
Slomski A
JAMA; 2012 Jan; 307(2):133. PubMed ID: 22235075
[No Abstract] [Full Text] [Related]
3. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.
Chou R; Croswell JM; Dana T; Bougatsos C; Blazina I; Fu R; Gleitsmann K; Koenig HC; Lam C; Maltz A; Rugge JB; Lin K
Ann Intern Med; 2011 Dec; 155(11):762-71. PubMed ID: 21984740
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of prostate cancer.
Naitoh J; Zeiner RL; Dekernion JB
Am Fam Physician; 1998 Apr; 57(7):1531-9, 1541-2, 1545-7. PubMed ID: 9556643
[TBL] [Abstract][Full Text] [Related]
5. Population-based assessment of determining predictors for quality of prostate cancer surveillance.
Chamie K; Williams SB; Hershman DL; Wright JD; Nguyen PL; Hu JC
Cancer; 2015 Dec; 121(23):4150-7. PubMed ID: 26307939
[TBL] [Abstract][Full Text] [Related]
6. Screening for prostate cancer: who and how often?
Schwartz K; Deschere B; Xu J
J Fam Pract; 2005 Jul; 54(7):586-96. PubMed ID: 16009085
[TBL] [Abstract][Full Text] [Related]
7. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
[TBL] [Abstract][Full Text] [Related]
8. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
9. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
10. Differences among men on active surveillance for very low-risk prostate cancer detected through population-based versus opportunistic prostate-specific antigen-screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Recker F; Kwiatkowski M
Urol Int; 2015; 94(3):330-6. PubMed ID: 25633871
[TBL] [Abstract][Full Text] [Related]
11. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen.
Zhang HF; Wang HL; Xu N; Li SW; Ji GY; Li XM; Pan YZ; Zhang L; Zhao XJ; Gao HW
Chin Med J (Engl); 2004 Jan; 117(1):67-70. PubMed ID: 14733776
[TBL] [Abstract][Full Text] [Related]
12. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
13. Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland.
Hegarty JM; Wallace M; Comber H
Am J Mens Health; 2008 Jun; 2(2):133-42. PubMed ID: 19477777
[TBL] [Abstract][Full Text] [Related]
14. Decision-Making in Prostate Cancer: Active Surveillance Over Other Treatment Options.
Bayliss D; Duff J; Stricker P; Walker K
Urol Nurs; 2016; 36(3):141-9. PubMed ID: 27501595
[TBL] [Abstract][Full Text] [Related]
15. Active surveillance: the Canadian experience.
Klotz L
Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
17. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
18. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
19. Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.
van Vugt HA; Roobol MJ; Venderbos LD; Joosten-van Zwanenburg E; Essink-Bot ML; Steyerberg EW; Bangma CH; Korfage IJ
Eur J Cancer; 2010 Feb; 46(3):669-77. PubMed ID: 20022239
[TBL] [Abstract][Full Text] [Related]
20. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]